FFFrancisco Dario Rocha Filho

Francisco Dario Rocha Filho

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Francisco Dario Rocha Filho has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Immunohistochemistry contribution in the diagnosis of splenic marginal zone lymphoma

    by Juliene Lima Mesquita, Yensy Mariana Zelaya Rosales, Yhasmine Delles Oliveira Garcia, Francisco Dario Rocha Filho, Beatriz Stela Gomes de Sousa Pitombeira Araujo, João Paulo de Vasconcelos Leitão, Jesus Irajacy Costa, Beatrice Araújo Duarte, João Vitor Araújo Duarte, Romélia Pinheiro Gonçalves Lemes, et al.

    Splenic marginal zone B-cell lymphoma is a rare type of non-Hodgkin B-cell lymphoma, without preference for sex, which affects individuals mainly over 50 years. In many cases, the disease is asymptomatic, with absent splenomegaly and lymphadenomegaly. The changes in the peripheral blood, when present, are lymphocytosis, anemia, and thrombocytopenia; cytopenias are mostly due to hypersplenism. The presence of B symptoms and increased LDH is rare1 , 2 . The immunophenotype pattern is characterized by pan-B cell expression with positive CD19, CD20, CD22, CD79a, IgM, and IgD. CD5 is found only in 15%, and CD23 in 30% of cases. It presents as the most common cytogenetic alteration the heterogeneous expressions of chromosome 7, the (9:14) (p13: q32), which overlaps the IgH and PAX-53 genes. The marrow infiltration patterns are highly variable and consist of nodular, paratrabecular, and interstitial4 , 5 . The finding of the intrasinusoidal pattern is more easily observed by CD20 or CD34 immunohistochemistry. Spleen histology shows micronodular infiltration of white pulp with biphasic pattern and a variable degree of red pulp involvement. Differential diagnosis should be made with other chronic B7 cell lymphoproliferative diseases5 .

  • Open Access

    Interstitial nephritis associated with nivolumab in a patient with hodgkin lymphoma

    by Deivide de Sousa Oliveira, Juliene Lima Mesquita, Yhasmine Delles Oliveira Garcia, Yensy Mariana Zelaya Rosales, Romélia Pinheiro Gonçalves Lemes, Francisco Dário Rocha Filho, Paula Frassinetti Castelo Branco Camurça Fernandes, Pastora Maria Araujo Duarte, Maria da Silva Pitombeira, Fernando Barroso Duarte


  • Open Access

    Bone Marrow Effects of High Dose Folic Acid Therapy in Chronic Idiopathic Thrombocytopenic Purpura.

    by Elizabeth Schulz, Rosangela Albuquerque Ribeiro Holanda, Francisco Dario Rocha Filho, Guilherme Alves de Lima Henn, Ricardo Alves Oliveira

    Chronic idiopathic thrombocytopenic purpura (CITP) is an autoimmune disorder characterized by the production of autoantibodies against specific platelet antigens and characterized by low platelet counts in peripheral blood over a period of at least 6 months. Corticosteroids have been generally used as first line therapy with serious side effects. Previously, we described the beneficial effect of high dose folic acid (HDFA), 5 to 20 mg PO daily), in the therapy of this disease. Presently, we report the treatment of two patients with severe thrombocytopenia with HDFA. A 46 year old splenectomized woman (P1) and a 32 year old non-splenectomized man (P2), who were moderately refractory to prednisone and prednisolone, had a previous history of undifferentiated connective tissue disease characterized by one episode of arthritis (P2 with a positive rheumatoid factor and morning stiffness). Both patients had normal serum folic acid and vitamin B12, and no signs of megaloblastic or dysplastic alterations were evidenced in bone marrow aspirates. Ham test was negative and CD55/CD59 values for both patients were equal to normal controls. Bone marrow biopsies were also performed prior to the treatment with folic acid (FA) to evidence a global decrease in bone marrow cellularity (30% in case 1 and 20% in case 2). Concomitant infections or other diseases were excluded. Prednisone was tapered slowly, and high dose folic acid administration was initiated at this time. P1 achieved complete remission (CR) in 5 months with slowly tapering of folic acid during one year, remaining with normal platelet counts after one more year with no treatment. P2 achieved sustained partial remission (PR) with platelet counts ranging 63 x 109L to 113 x109/L. Interestingly, sequential bone marrow biopsies performed 2 years after the beginning of HDFA therapy revealed a marrow cellularity of 50% and 35% for P1 and P2, respectively. We demonstrated that the successful CR and PR to HDFA are associated with a significant increase in the overall bone marrow cellularity in both cases (20% in P1 and 15% in P2). Apoptotic features in idiopathic thrombocytopenic purpura (ITP) were characterized by Houwerzijl et al who demonstrated apoptosis and para-apoptosis as ultrastructural alterations in bone marrow megacaryocytes, supportive of ineffective thrombopoiesis as an underlying phenomenon in this study. Buemi et al demonstrated that addition of folic acid to the medium of vascular smooth muscle cells in culture inhibited the percentage of apoptotic and necrotic cells through a decrease in homocysteine concentration. The exact mechanism through which high dose folic acid is able to increase platelets measured in peripheral blood of patients with ITP and induce sustained CR and PR is so far unknown and remains to be explained. However, the present response to HDFA suggest a qualitative and especially quantitative role for this drug in protecting and upgrading the hematopoietic bone marrow and, consequently, restoring the platelet production in these 2 patients.